Please select the option that best describes you:
Do you use MRD testing to guide maintenance therapy discontinuation in newly diagnosed non-high risk myeloma patients?
Please elaborate on both transplant-ineligible (not deferred) versus post-autologous transplant settings?
Answer from: Medical Oncologist at Academic Institution
Major bias, incoming!The short answer is: yes, I use MRD to guide de-escalation and ultimately discontinuation in standard-risk patients with myeloma.Much of that sentiment comes from our work at the University of Chicago called MRD2STOP, where we allow patients to stop treatment if they are sustain...
Sign in or Register to read more